SubsidieMeestersRescue Pacing for Congenital Complete Heart Block
This project aims to develop a gene therapy using adenoviral vectors to increase heart rates in fetuses with congenital complete heart block, enabling safe pacemaker implantation post-birth.
Projectdetails
Introduction
Congenital heart block is the most commonly observed type of foetal bradycardia, occurring in one in 15,000 live births. A significant subset of foetuses develops towards congenital complete heart block (CCHB), i.e., complete failure of the electrical excitation wavefront to be conducted over the atrioventricular (AV) node.
Severity of CCHB
CCHB is the most severe and life-threatening cardiac arrhythmia in utero. Current medicinal treatments cannot significantly alter the cause of CCHB, and therapeutic attempts at human foetal cardiac pacing have been unsuccessful.
Project Objective
For CCHB patients at high risk for life-threatening disease progression and death due to severe bradycardia before 34 weeks of gestation, this project develops a gene therapy medicinal product (GTMP) that is based on adenoviral vector-mediated ion channel overexpression.
Expected Outcomes
The aim is to transiently increase heart rates over the course of several months. When successful, such a GTMP would rescue these patients and allow for permanent pacemaker implantation in the first months after birth.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 31-1-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- STICHTING AMSTERDAM UMCpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A Chemogenetic Approach for the Treatment of Atrial FibrillationDevelop a targeted, non-destructive chemogenetic treatment for atrial fibrillation to safely modulate cardiac excitability and prevent atrial remodeling. | ERC Proof of... | € 150.000 | 2025 | Details |
Reversible and irreversible cardiac electroporation: Establishing the fundamentals to advance cardiac treatmentsThis project aims to understand cardiac electroporation mechanisms to develop methods for effective irreversible and reversible treatments for atrial fibrillation and ischemic heart disease. | ERC Starting... | € 1.500.000 | 2024 | Details |
Translational optoelectronic control of cardiac rhythm in atrial fibrillationThis project aims to develop a shock-free, optoelectronic method for controlling cardiac rhythm in atrial fibrillation using engineered 3D heart models and advanced monitoring systems. | ERC Consolid... | € 1.999.999 | 2023 | Details |
Unique non-invasive pace-mapping system to identify subjects at risk of arrhythmic sudden deathDevelop a non-invasive mapping and pacing system to detect cardiac signals for predicting sudden cardiac death, improving early diagnosis and management of heart disease. | ERC Advanced... | € 2.488.400 | 2022 | Details |
Unraveling pacemaker (dys)function using novel stem cell-derived human heart modelsThis project aims to enhance understanding of sinoatrial node function and its dysfunction in heart rhythm disorders using innovative in vitro models derived from human pluripotent stem cells. | ERC Starting... | € 1.797.105 | 2024 | Details |
A Chemogenetic Approach for the Treatment of Atrial Fibrillation
Develop a targeted, non-destructive chemogenetic treatment for atrial fibrillation to safely modulate cardiac excitability and prevent atrial remodeling.
Reversible and irreversible cardiac electroporation: Establishing the fundamentals to advance cardiac treatments
This project aims to understand cardiac electroporation mechanisms to develop methods for effective irreversible and reversible treatments for atrial fibrillation and ischemic heart disease.
Translational optoelectronic control of cardiac rhythm in atrial fibrillation
This project aims to develop a shock-free, optoelectronic method for controlling cardiac rhythm in atrial fibrillation using engineered 3D heart models and advanced monitoring systems.
Unique non-invasive pace-mapping system to identify subjects at risk of arrhythmic sudden death
Develop a non-invasive mapping and pacing system to detect cardiac signals for predicting sudden cardiac death, improving early diagnosis and management of heart disease.
Unraveling pacemaker (dys)function using novel stem cell-derived human heart models
This project aims to enhance understanding of sinoatrial node function and its dysfunction in heart rhythm disorders using innovative in vitro models derived from human pluripotent stem cells.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transcription Factor Gene Therapy for BradyarrhythmiasPacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization. | EIC Transition | € 2.499.968 | 2023 | Details |
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn DeathThe NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment. | EIC Pathfinder | € 4.546.205 | 2023 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
Transcription Factor Gene Therapy for Bradyarrhythmias
PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death
The NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.